Study Confirms No Benefit to Taking Fluvoxamine for COVID-19 Symptoms
Environmental influences on Child Health Outcomes NIHA study led by the Duke Clinical Research Institute (DCRI) in partnership with Vanderbilt University found no symptomatic or clinical benefit to taking the antidepressant fluvoxamine at a dosage of 100 mg twice daily for 13 days for the treatment of mild-to-moderate COVID-19 symptoms.